Immunitybio Ev To Sales from 2010 to 2024

IBRX Stock  USD 5.04  0.06  1.18%   
Immunitybio EV To Sales yearly trend continues to be fairly stable with very little volatility. EV To Sales is likely to outpace its year average in 2024. EV To Sales is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. View All Fundamentals
 
EV To Sales  
First Reported
2010-12-31
Previous Quarter
4.8 K
Current Value
K
Quarterly Volatility
5.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.8 M, Interest Expense of 135.7 M or Selling General Administrative of 91.7 M, as well as many indicators such as Price To Sales Ratio of 6.7 K, Dividend Yield of 0.0 or Days Sales Outstanding of 1.8 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Ev To Sales Growth Pattern

Below is the plot of the Ev To Sales of Immunitybio over the last few years. It is the Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue. Immunitybio's EV To Sales historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
Ev To Sales10 Years Trend
Slightly volatile
   Ev To Sales   
       Timeline  

Immunitybio Ev To Sales Regression Statistics

Arithmetic Mean5,144
Geometric Mean1,490
Coefficient Of Variation99.79
Mean Deviation4,174
Median4,517
Standard Deviation5,133
Sample Variance26.3M
Range16.9K
R-Value0.32
Mean Square Error25.4M
R-Squared0.10
Significance0.24
Slope368.81
Total Sum of Squares368.9M

Immunitybio Ev To Sales History

2024 7001.43
2023 4846.66
202211 K
2021 3031.16
2020 8840.35
2019 659.21
2018 1742.18

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Ev To Sales, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EV To Sales4.8 KK

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.